[1]霍宏志,梁金,柴尔青.TM4SF1与脑胶质瘤病理分级及预后的相关性[J].中国临床神经外科杂志,2022,27(06):447-451.[doi:10.13798/j.issn.1009-153X.2022.06.005]
 HUO Hong-zhi,LIANG Jin,CHAI Er-qing.Relationship between expression of TM4SF1 in glioma tissues and malignancy and prognosis of gliomas[J].,2022,27(06):447-451.[doi:10.13798/j.issn.1009-153X.2022.06.005]
点击复制

TM4SF1与脑胶质瘤病理分级及预后的相关性()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年06期
页码:
447-451
栏目:
论著
出版日期:
2022-06-30

文章信息/Info

Title:
Relationship between expression of TM4SF1 in glioma tissues and malignancy and prognosis of gliomas
文章编号:
1009-153X(2022)06-0447-05
作者:
霍宏志梁金柴尔青
730000 兰州,甘肃省人民医院神经外科(霍宏志、梁金、柴尔青)
Author(s):
HUO Hong-zhi LIANG Jin CHAI Er-qing
Department of Neurosurgery, Gansu Provincial People's Hospital, Lanzhou 730000, China
关键词:
脑胶质瘤跨膜四蛋白超家族成员 1(TM4SF1)病理分级生存预后
Keywords:
Glioma Transmembrane-4-L-six-family-1 (TM4SF1) Pathological grade Prognosis Risk factor
分类号:
R739.41;Q786
DOI:
10.13798/j.issn.1009-153X.2022.06.005
文献标志码:
A
摘要:
目的 探讨跨膜四蛋白超家族成员1(TM4SF1)与脑胶质瘤病理分级及预后的相关性。方法 应用生信分析方法,计算机检索TCGA数据库,采用GEPIA分析TM4SF1表达胶质瘤病理分级及生存预后的关系。收集2014年3月至2017年4月手术切除的脑胶质瘤83例[低级别胶质瘤(LGG)35例和高级别胶质瘤(HGG)48例]和23例颅脑损伤内减压术切除的非肿瘤脑组织为对照,采用免疫组化染色法检测组织TM4SF1表达情况,术后随访4年,记录无进展生存期(PFS)和总生存期(OS)。结果 生信分析显示:胶质瘤组织TM4SF1 mRNA表达量明显高于正常脑组织(P<0.05);而且,HGG组织TM4SF1 mRNA表达量明显高于LGG组织(P<0.05)。TM4SF1高表达HGG病人OS较低表达病人明显缩短(P<0.05);TM4SF1高表达LGG病人PFS、OS较低表达病人均明显缩短(P<0.05)。临床病例分析显示:胶质瘤TM4SF1高表达率[50.60%(42/83)]明显高于非肿瘤脑组织[13.04%(3/23);P<0.01];HGG组织TM4SF1高表达率[60.42%(29/48)]明显高于LGG组织[37.14%(13/35);P<0.05];多因素Cox比例回归风险模型分析显示,TM4SF1高表达是胶质瘤病人生存预后不良的独立危险因素(P<0.05);生存曲线分析显示,TM4SF1 高表达病人中位PFS和OS较低表达病人明显缩短(P<0.05)。结论 脑胶质瘤TM4SF1呈高表达,与肿瘤病理分级、不良生存预后有关。
Abstract:
Objective To investigate the relationship between the expression of transmembrane-4-L-six-family-1 (TM4SF1) in glioma tissues and the malignancy and prognosis of gliomas. Methods The TCGA database was searched by computer to analyze the relationship between TM4SF1 expression and pathological grade and survival prognosis of glioma patients using bioinformatics analysis method GEPIA. The expressions of TM4SF1 were detected using immunohistochemical staining in glioma tissues obtained from 83 glioma patients [35 low-grade glioma (LGG) and 48 high-grade glioma (HGG)] who underwent surgery from March 2014 to April 2017 and in non-tumor tissues obtained from 23 patients with traumatic brain injury who underwent decompression. These 83 glioma pstients were followed up for 4 years, and the progression-free survival (PFS) and overall survival (OS) were recorded. Results Bioinformatics analysis showed that the expression of TM4SF1 mRNA in glioma tissues was significantly higher than that in normal brain tissue (P<0.05); the expression of TM4SF1 mRNA in HGG tissues was significantly higher than that in LGG tissues (P<0.05); the OS of HGG patients with high expression of TM4SF1 was significantly shorter than that of HGG patients with low expression of TM4SF1 (P<0.05); the PFS and OS of LGG patients with high expression of TM4SF1 were significantly shorter than that of LGG patients with low expression of TM4SF1 (P<0.05). Analysis of clinical cases showed that the high expression rate of TM4SF1 in glioma tissues [50.60% (42/83)] was significantly higher than that in non-tumor brain tissues [13.04% (3/23); P<0.01]; the high expression rate of TM4SF1 in HGG tissues [60.42% (29/48)] was significantly higher than that of LGG tissue [37.14% (13/35); P<0.05]; multivariate Cox proportional regression hazard model analysis showed that high expression of TM4SF1 was an independent risk factor of poor survival prognosis in glioma patients (P<0.05); survival curve analysis showed that the median PFS and OS of patients with high TM4SF1 expression were significantly shorter than those of patients with low TM4SF1 expression (P<0.05). Conclusions The expression of TM4SF1 in gliomas is up-regulated, which is related to the pathological grade and poor survival prognosis.

参考文献/References:

[1] Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassi-fications and their clinical significance [J]. Neurotherapeutics, 2017, 14(2): 284-297.
[2] Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review [J]. Neuro Oncol, 2014, 16(7): 896-913.
[3] 姚红羽,阳志军. TM4SF1在恶性肿瘤研究中的进展[J]. 医学与哲学(B),2018,13(3):60-63.
[4] 刘佳艺,邵梦楠,檀燕君,等. 口腔鳞状细胞癌组织中TM4SF1 mRNA的筛选及其蛋白的表达变化观察[J]. 山东医药,2020,60(6):55-57.
[5] Wesseling P, Capper D. WHO 2016 classification of gliomas[J]. Neuropathol Appl Neurobiol, 2018, 44(2): 139-150.
[6] Gao C, Yao H, Liu H, et al. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer [J]. BMC Cancer, 2019, 19(1): 237-248.
[7] Huang YK, Fan XG, Qiu F. TM4SF1 promotes proliferation, invasion, and metastasis in human liver cancer cells [J]. Int J Mol Sci, 2016, 17(5): 661-679.
[8] Cao R, Wang G, Qian K, et al. TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells [J]. Cancer Lett, 2018, 414: 278-293.
[9] Park YR, Kim SL, Lee MR, et al. MicroRNA-30a-5p (miR-30a) regulates cell motility and EMT by directly targeting oncogenic TM4SF1 in colorectal cancer [J]. J Cancer Res Clin Oncol, 2017, 143(10): 1915-1927.
[10] Peng XC, Zeng Z, Huang YN, et al. Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer [J]. Int J Colorectal Dis, 1997, 12(1): 19-23.
[11] Xu D, Yang F, Wu K, et al. Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 via AKT [J]. Cancer Biol Ther, 2020, 21(4): 354-363.
[12] Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas--implications for classification and therapy [J]. Nat Rev Clin Oncol, 2017, 14(7): 434-452.

相似文献/References:

[1]付 锴 江普查 宫 睿 王 伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
 FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(06):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳 琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫 珊 徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
 YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(06):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮 夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
 LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民 褚会松 田 甜 王昆鹏 杨国军 杨立军 王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
 HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(06):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述 王 辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰 姚庆和 李晓辉 龙宇波 陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
 GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(06):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘 靖 吴立权 黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
 LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(06):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘 炎 杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明 胡新华 刘 永 陈 玖 刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
(2022-03-16收稿,2022-04-25修回)
通讯作者:柴尔青,E-mail:gyj-123@163.com
更新日期/Last Update: 2022-07-31